PMN

ProMIS Neurosciences Inc

12.60

Sep 04 • 3:59 PM ET -0.30 (-2.33%)

12.99

Aftermarket • 7:06 PM ET +0.39 (3.06%)

Healthcare Biotechnology Canada Micro NASD

Peers: BCTX CLRB JSPR LGVN MRKR NXTC PLUR TPST TRAW VTGN

Scroll to Statements

Index	-
Market Cap	112.99M
Enterprise Value	59.53M
Income	-42.23M
Sales	0.00M
Book/sh	5.51
Cash/sh	5.96
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	11
IPO	Jan 16, 2007

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.29
P/C	2.11
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.85
Current Ratio	7.85
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-13.43
EPS next Y	-3.81
EPS next Q	-1.27
EPS this Y	77.42%
EPS next Y	25.36%
EPS next 5Y	47.77%
EPS past 3/5Y	27.86% -0.39%
Sales past 3/5Y	- -
EPS Y/Y TTM	-169.38%
Sales Y/Y TTM	-
EPS Q/Q	82.32%
Sales Q/Q	-
Earnings	Aug 13 AMC
EPS/Sales Surpr.	7.15% -

Insider Own	21.59%
Insider Trans	0.43%
Inst Own	60.80%
Inst Trans	0.75%
ROA	-127.57%
ROE	-172.30%
ROIC	-85.48%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-11.84%
SMA50	-8.98%
SMA200	1.30%
Trades

Shs Outstand	8.97M
Shs Float	7.03M
Short Float	4.00%
Short Ratio	3.36
Short Interest	0.28M
52W High	27.40 -54.01%
52W Low	6.27 100.96%
Volatility	9.32% 7.73%
ATR (14)	1.15
RSI (14)	40.41
Beta	-0.27
Rel Volume	0.29
Avg Volume	83.59K
Volume	24,087

Perf Week	-8.60%
Perf Month	-5.48%
Perf Quarter	38.01%
Perf Half Y	-46.15%
Perf YTD	84.62%
Perf Year	17.21%
Perf 3Y	-75.41%
Perf 5Y	-94.72%
Perf 10Y	-93.23%
Recom	1.00
Target Price	43.50
Prev Close	12.90
Price	12.60
Change %	-2.33%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-27-26	Initiated	Chardan Capital Markets	Buy	$20

Sep-01-26 08:00AM	ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September (GlobeNewswire)
Aug-14-26 01:02AM	ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and ... (GuruFocus.com)
Aug-13-26 04:00PM	ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights (GlobeNewswire)
Aug-03-26 04:00PM	ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026 (GlobeNewswire)
Jul-28-26 08:25AM	ProMIS Neurosciences Shares Climb on Positive Interim Alzheimer's Trial Safety Results (InvestorsHub) +23.89%
06:00AM	Loading…
06:00AM	ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer's Disease Trial (GlobeNewswire)
Jul-27-26 04:00PM	ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer's Disease (GlobeNewswire)
Jul-14-26 02:30AM	ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026 (GlobeNewswire) +6.72%
May-28-26 10:13AM	ProMIS Neurosciences to Participate in Upcoming Conferences in June (GlobeNewswire)
May-12-26 06:30AM	ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights (GlobeNewswire)
Apr-13-26 07:30AM	ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference (Newsfile)
Mar-25-26 08:00AM	ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights (GlobeNewswire) -9.06%
Mar-18-26 08:00AM	ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD) (GlobeNewswire) -13.04%
Feb-09-26 08:35AM	Five US Stocks See Over $185M in Insider Buying, with Soho House and WR Berkley Leading the Pack (24/7 Wall St.)
Feb-04-26 04:05PM	ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) -16.29%
08:00AM	Loading…
Jan-30-26 08:00AM	ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing (GlobeNewswire) +17.95%
Dec-18-25 07:30AM	ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease (GlobeNewswire) -5.61%
Dec-10-25 07:30AM	ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk (GlobeNewswire) +12.00%
Dec-01-25 07:30AM	ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310 (GlobeNewswire)
07:00AM	ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-24-25 08:00AM	ProMIS Neurosciences Announces Reverse Stock Split (GlobeNewswire) -22.36%
Nov-12-25 07:00AM	ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights (GlobeNewswire)
Nov-03-25 04:05PM	ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
Oct-22-25 07:30AM	ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group (GlobeNewswire)
Sep-18-25 09:10AM	Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics (PR Newswire)
Sep-03-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -14.76%
07:00AM	ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310 (GlobeNewswire)
Aug-13-25 07:00AM	ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights (GlobeNewswire)
Jul-29-25 08:00AM	ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference (GlobeNewswire) -6.67%
Jul-28-25 07:00AM	ProMIS Neurosciences Announces Private Placement Financing (GlobeNewswire) -8.76%
07:01AM	Loading…
Jul-22-25 07:01AM	ProMIS Neurosciences Announces Private Placement Financing (GlobeNewswire) -26.79%
07:00AM	ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jul-21-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +154.49%
08:00AM	ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease (GlobeNewswire)
Jun-17-25 07:00AM	ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference (GlobeNewswire)
May-12-25 07:30AM	ProMIS Neurosciences Announces First Quarter 2025 Financial Results (GlobeNewswire)
Mar-31-25 07:00AM	ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights (GlobeNewswire)
Mar-24-25 07:00AM	ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference (GlobeNewswire)
Mar-13-25 07:00AM	ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting (GlobeNewswire)
Mar-11-25 07:30AM	ProMIS Neurosciences to Participate in the 37th Annual Roth Conference (GlobeNewswire)
Feb-25-25 07:00AM	ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease (GlobeNewswire) -6.19%
Jan-29-25 07:30AM	ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-13-25 10:30AM	ProMIS Neurosciences Issues Letter to Shareholders (GlobeNewswire)
Jan-10-25 07:00AM	ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's Disease (GlobeNewswire)
Nov-26-24 07:00AM	ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
Nov-14-24 09:15AM	ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
Nov-12-24 07:00AM	ProMIS Neurosciences to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire)
Oct-30-24 08:00AM	ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference (GlobeNewswire) +5.83%
Oct-13-24 02:58PM	ProMIS Neurosciences, Inc. (PMN): Analysts Are Bullish On This Undervalued Canadian Stock Now (Insider Monkey)
Sep-12-24 07:00AM	ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences (GlobeNewswire)
Sep-05-24 07:00AM	ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Aug-08-24 07:00AM	ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire) -11.51%
Aug-06-24 07:00AM	ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology (GlobeNewswire) +18.33%
Aug-01-24 07:00AM	ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024 (GlobeNewswire)
Jul-30-24 08:30AM	ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference (GlobeNewswire) -17.43%
Jul-26-24 08:35AM	ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial (GlobeNewswire) -20.70%
08:30AM	ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing (GlobeNewswire)
May-15-24 09:54AM	PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024 (InvestorPlace) -7.22%
May-14-24 04:01PM	ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
Apr-30-24 07:00AM	ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies (GlobeNewswire)
Apr-09-24 07:00AM	ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS (GlobeNewswire)
Apr-04-24 07:00AM	ProMIS Neurosciences to Present in Upcoming Investor Conferences in April (GlobeNewswire)
Apr-01-24 10:53PM	PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023 (InvestorPlace) +7.33% +10.15%
04:15PM	ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights (GlobeNewswire)
Mar-11-24 07:00AM	ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio (GlobeNewswire)
Feb-22-24 07:00AM	ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire) -10.14%
Jan-22-24 07:00AM	ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine (GlobeNewswire) +7.24%
Jan-08-24 07:00AM	ProMIS Neurosciences Issues Letter to Shareholders (GlobeNewswire) +5.45%
Jan-03-24 07:00AM	ProMIS Neurosciences, Inc. Announces Leadership Transition (GlobeNewswire) -7.82%
Dec-20-23 07:00AM	ProMIS Neurosciences Announces Publication on Novel Target for ALS (GlobeNewswire)
Nov-20-23 07:00AM	ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease (GlobeNewswire) +6.67%
Nov-14-23 04:30PM	ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire) -12.22% +9.36%
Sep-08-23 07:00AM	ProMIS Neurosciences Closes $20.4 Million Private Placement Financing (GlobeNewswire)
Sep-06-23 12:18PM	ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-21-23 04:12PM	ProMIS Neurosciences Announces $20.4 Million Private Placement Financing (GlobeNewswire) -9.14% +20.75%
Aug-14-23 05:33PM	ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire) -8.33%
Jul-17-23 07:00AM	ProMIS Showcases Preclinical Data at the Alzheimers Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimers Pipeline (GlobeNewswire) +120.28%
Jul-14-23 07:45AM	ProMIS Announces Completion of Continuance (GlobeNewswire)
Jul-10-23 07:55AM	ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange (GlobeNewswire) -8.11%
Jun-30-23 08:00AM	ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved (GlobeNewswire)
Jun-29-23 08:00AM	CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time (GlobeNewswire)
May-15-23 05:00PM	ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire) -8.16%
May-08-23 09:00AM	ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimers Disease (GlobeNewswire)
Apr-25-23 05:00PM	Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimers Disease (GlobeNewswire)
Apr-24-23 07:30AM	ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimers Disease and ALS at American Academy of Neurology Annual Meeting (GlobeNewswire) +8.31%
Apr-10-23 07:30AM	ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310 (GlobeNewswire)
Mar-29-23 08:30AM	Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023 (GlobeNewswire)

ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.

Co-Founder & ChairmanMr. Eugene W. Williams

CEOMr. Neil K. Warma M.B.A.

Co-FounderDr. Neil R. Cashman M.D.

Chief Development OfficerDr. Johanne Kaplan Ph.D.

Ph.D.Dr. Larry Douglas Altstiel M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kaplan Johanne	Chief Development Officer	Aug 05 '26	Buy	13.30	2,280	30,324	6,221	Aug 07 04:00 PM
Kirwin Patrick D.	Director	Apr 22 '26	Buy	11.33	4,000	45,320	4,653	Apr 23 09:25 PM
Williams Eugene	Director	Mar 05 '26	Buy	24.40	2,000	48,800	12,397	Mar 06 07:28 AM
Williams Eugene	Director	Mar 04 '26	Buy	24.00	2,000	48,000	10,397	Mar 04 06:08 PM
Williams Eugene	Director	Mar 02 '26	Buy	22.53	1,000	22,530	7,397	Mar 04 06:08 PM
Williams Eugene	Director	Mar 03 '26	Buy	21.89	1,000	21,890	8,397	Mar 04 06:08 PM
Kaplan Johanne	Chief Development Officer	Feb 19 '26	Buy	15.35	1,629	25,005	3,941	Feb 23 08:31 AM
ABG Management Ltd.	10% Owner	Feb 03 '26	Buy	12.13	700,741	8,499,988	943,090	Feb 05 07:00 PM
Milbury Max A.	Principal Accounting Officer	Oct 03 '25	Buy	0.49	30,392	14,929	45,389	Oct 06 09:12 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PMN

ProMIS Neurosciences Inc

Upgrade your Finviz experience